Interleukin-33 as an early predictor of cetuximab treatment efficacy in patients with colorectal cancer.

ABSTRACT:

Background

Cetuximab is used for colorectal cancer (CRC) treatment. However, the early biomarker of treatment efficacy of cetuximab has not been identified.

Methods

After 1 year of cetuximab treatment, patients were divided into an effective group and an ineffective group. The interleukin-33 (IL-33) level and the distribution of lymphatic cells in patients were investigated by analyzing the peripheral blood mononuclear cells via flow cytometry analysis and ELISA. The correlation between IL-33 immunomodulatory effect and cetuximab treatment efficacy was determined through experiments in vivo and in vitro.

Results

The IL-33 level in the peripheral blood was increased at 4 weeks after cetuximab administration of effective group, meanwhile, the osteopontin (OPN) was reduc

SUBMITTER: Zhang X 

PROVIDER: S-EPMC8633246 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature